Evidence map›Paper›PMID 42261238›Full record

ArticleEmerging microbes & infections2026

Transmitted and pretreatment drug resistance among 69 HIV-1 CRFs in China: the first systematic analysis.

Xiaoyi Yin, Bin Zhao, Minghui An, Danni Wang, Zhihan Liu, Hong Shang, Xiaoxu Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoyi YinState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), The First Hospital of China Medical University, China Medical University, Shenyang, People's Republic of China.
Bin ZhaoState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), The First Hospital of China Medical University, China Medical University, Shenyang, People's Republic of China.
Minghui AnState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), The First Hospital of China Medical University, China Medical University, Shenyang, People's Republic of China.
Danni WangNational Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang, People's Republic of China.
Zhihan LiuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), The First Hospital of China Medical University, China Medical University, Shenyang, People's Republic of China.
Hong ShangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), The First Hospital of China Medical University, China Medical University, Shenyang, People's Republic of China.
Xiaoxu HanNational Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, an increasing number of HIV-1 circulating recombinant forms (CRFs) have been identified in China. This study presented the first systematic analysis of the molecular epidemiological characteristics and drug resistance mutations (DRMs) profiles of all 69 CRFs identified in China up to 2025, comprising 13 first-generation, 45 second-generation, 10 third-generation, and one fourth-generation CRF . Several CRFs exhibited moderate transmitted drug resistance (5-15%) and elevated pretreatment drug resistance (10.8-55.1%). Notably, V179D/E were prevalent across multiple CRFs and, in combination with other DRMs, may contribute to reduced susceptibility to non-nucleoside reverse transcriptase inhibitors (NNRTIs). These findings provided critical surveillance data on DRMs and baseline data for NNRTIs selection in China, underscoring the necessity of phenotypic validation in novel CRFs harbouring natural DRMs.

Indexed as

Anti-HIV AgentsDrug Resistance, ViralHIV-1HIV InfectionsChinaGenotypeHumansMutationPhylogenyReverse Transcriptase InhibitorsAnti-HIV AgentsReverse Transcriptase InhibitorsChinaCirculating recombinant forms (CRFs)pretreatment drug resistance (PDR)Transmitted drug resistance (TDR)v179d/E

Identifiers

PMID42261238
PMCPMC13250860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.